BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 3105865)

  • 1. Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice.
    Talmadge JE; Tribble HR; Pennington RW; Phillips H; Wiltrout RH
    Cancer Res; 1987 May; 47(10):2563-70. PubMed ID: 3105865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical approaches to the treatment of metastatic disease: therapeutic properties of rH TNF, rM IFN-gamma, and rH IL-2.
    Talmadge JE; Black PL; Tribble H; Pennington R; Bowersox O; Schneider M; Phillips H
    Drugs Exp Clin Res; 1987; 13(6):327-37. PubMed ID: 3115744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and gamma-interferon.
    Hori K; Ehrke MJ; Mace K; Mihich E
    Cancer Res; 1987 Nov; 47(22):5868-74. PubMed ID: 3117358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
    Talmadge JE; Phillips H; Schindler J; Tribble H; Pennington R
    Cancer Res; 1987 Nov; 47(21):5725-32. PubMed ID: 3499218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease.
    Black PL; Phillips H; Tribble HR; Pennington R; Schneider M; Talmadge JE
    J Cell Biochem; 1988 Apr; 36(4):377-92. PubMed ID: 3132467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages.
    Hori K; Mihich E; Ehrke MJ
    Cancer Res; 1989 May; 49(10):2606-14. PubMed ID: 2496917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
    Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
    Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of recombinant human tumor necrosis factor on the induction of murine macrophage tumoricidal activity.
    Hori K; Ehrke MJ; Mace K; Maccubbin D; Doyle MJ; Otsuka Y; Mihich E
    Cancer Res; 1987 Jun; 47(11):2793-8. PubMed ID: 2882835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo.
    Sayers TJ; Wiltrout TA; McCormick K; Husted C; Wiltrout RH
    Cancer Res; 1990 Sep; 50(17):5414-20. PubMed ID: 2117482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic alkalinization inhibits the ability of flavone acetic acid to augment natural killer activity, induce cytokine gene expression, and synergize with interleukin 2 for the treatment of murine renal cancer.
    Futami H; Hornung RL; Back TT; Bull R; Gruys E; Wiltrout RH
    Cancer Res; 1990 Dec; 50(24):7926-31. PubMed ID: 2253233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer.
    Mace KF; Hornung RL; Wiltrout RH; Young HA
    Cancer Res; 1990 Mar; 50(6):1742-7. PubMed ID: 1689611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines.
    Schiller JH; Bittner G; Storer B; Willson JK
    Cancer Res; 1987 Jun; 47(11):2809-13. PubMed ID: 3105867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
    Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
    Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of tumor necrosis factor by rIFN-gamma-primed C3H/HeJ (Lpsd) macrophages requires the presence of lipid A-associated proteins.
    Hogan MM; Vogel SN
    J Immunol; 1988 Dec; 141(12):4196-202. PubMed ID: 3143760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and cytokine dependent monocyte-mediated leukemic cell death: modulation by interferon-gamma and tumor necrosis factor-alpha.
    van de Loosdrecht AA; Beelen RH; Ossenkoppele GJ; Broekhoven MG; Langenhuijsen MM
    Exp Hematol; 1993 Mar; 21(3):461-8. PubMed ID: 8440344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The induction and augmentation of macrophage tumoricidal responses by platelet-activating factor.
    Howard AD; Erickson KL
    Cell Immunol; 1995 Aug; 164(1):105-12. PubMed ID: 7634340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bryostatin-1 and IFN-gamma synergize for the expression of the inducible nitric oxide synthase gene and for nitric oxide production in murine macrophages.
    Taylor LS; Cox GW; Melillo G; Bosco MC; Espinoza-Delgado I
    Cancer Res; 1997 Jun; 57(12):2468-73. PubMed ID: 9192827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro growth inhibition of cisplatin-resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-gamma by virtue of collateral sensitivity.
    Hong WS; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Takahashi H; Nakano H; Nakagawa K; Twentyman PR
    Jpn J Cancer Res; 1987 Nov; 78(11):1274-80. PubMed ID: 3121562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.